BRAXX Biotech Co., Ltd.

【AEA 2017 Alumni】
Esophageal cancer is the eighth most common cancer in the world. There are over 450,000 new cases each year, and over 70% of whom are in Asia. In the esophageal cancer treatments, brachytherapy has advantages of high doses, high accuracy and high complete response rate, but its drawback is the fatal side effect. BRAXX Biotech develops an innovative solution to improve the therapeutic efficacy and avoid the side effects in traditional brachytherapy procedures. We dedicate to provide a better therapeutic environment for esophageal cancer patients.

President and Chairman

Nominated by

Chief Operating Officer,
Center for Industry Collaboration and Innovation Incubation, National Chengchi University
BRAXX Biotech is the pioneer in the field of radiology. Starting from the clinical unmet need, we develop the new generation brachytherapy applicator to provide a novel and advanced therapeutic method for cancer patients. We have finished the patent deployment of our core technology, designed and manufactured of the prototype and are planning for the clinical trial. The executive team of BRAXX are composed of experts with experience in clinical medicine, radiotherapy, marketing, regulatory affairs and intellectual property to maximize the product value and accelerate the development procedure.